General Inflammation Testing (CRP and ESR) — Coverage and Reimbursement Guidance
Customize your policy alerts
Sign up for all blue cross blue shield - tennessee policy alerts
Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.
Monitor payer policy activity
Coverage and reimbursement guidance for laboratory measurement of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) for evaluation and monitoring of inflammatory conditions; applies to Blue Cross Blue Shield - Tennessee members and providers submitting claims.
No material clinical or coverage changes in this revision.
Coverage Criteria
Covered Indications and Uses
Monitoring and evaluation of inflammatory diseases
Reimbursement table guidance: test preference and monitoring frequency for covered indications
Providers should follow listed test preference per indication.
Evaluation and supportive diagnosis of periprosthetic joint infection (PJI)
Evaluation and supportive diagnosis of periprosthetic joint infection (PJI)
Berbari et al. meta-analysis and Parvizi/MSIS guidance.
Staging and follow-up of Classic Hodgkin Lymphoma
Staging and follow-up of Classic Hodgkin Lymphoma
Per NCCN and ACR follow-up guidance.
Workup and monitoring of polymyalgia rheumatica and Castleman disease
Workup and monitoring of polymyalgia rheumatica and Castleman disease
Per BSR/BHPR for PMR and NCCN for Castleman disease.
Rheumatoid arthritis disease activity assessment
Rheumatoid arthritis disease activity assessment
Per ACR, EULAR, NCC-CC and large cohort studies (Hamann et al., Watson et al.).
Diagnosis and monitoring of GCA, PMR, RA, SLE, PJI, pediatric AHO, MIS-C, and other inflammatory conditions where CRP/ESR are part of validated measures or algorithms
Diagnosis and monitoring of inflammatory conditions where CRP/ESR are part of validated measures or algorithms
Guideline recommendations summarized from BSR/BHPR, ACR, EULAR, MSIS, PIDS/IDSA.
Inflammatory and rheumatologic conditions recommended by specialty guidelines
Inflammatory and rheumatologic conditions recommended by specialty guidelines
See reimbursement table and referenced guidelines for details.
Rheumatologic diseases and evaluation of suspected infection or PJI — cited via guideline and research references
Rheumatologic diseases and evaluation of suspected infection or PJI — cited via guideline and research references
Bibliography lists the detailed citations.
Coding and Numeric Thresholds
| No codes listed |
| No codes listed |
Recommended Testing Frequency
Provider Actions and Documentation
Condition documentation and general exam guidance
Measure ESR and/or CRP only when clinically indicated. Coverage is designated based on a diagnosed or suspected inflammatory condition; documentation must state the diagnosis or suspected condition. Measurement of CRP and/or ESR during a routine general exam without abnormal findings does not meet coverage criteria and may be denied. If there is any conflict with applicable government policy (LCD/NCD or state Medicaid), the government policy takes precedence.
- Condition documentation required: Document the diagnosed or suspected inflammatory condition when ordering ESR and/or CRP.
- Routine general exam: CRP/ESR during a general exam without abnormal findings does not meet coverage criteria.
Rheumatoid arthritis — active disease monitoring
For rheumatoid arthritis (RA) with active disease, monitor disease activity and inflammatory markers regularly. Guidelines recommend measuring CRP and key components of disease activity (using a composite score such as DAS28) monthly in people with recent-onset active RA until disease is controlled, and using CRP (or ESR within DAS28) every 1–3 months during active disease as part of treatment decision-making.
- RA active disease monitoring guidance: measure CRP and disease activity (eg, DAS28, CDAI, SDAI) monthly in recent-onset active RA; during active disease assess CRP (or ESR in validated composite scores) every 1–3 months.
Giant cell arteritis — baseline labs and documentation
When initiating high‑dose glucocorticoids for suspected giant cell arteritis (GCA), document clinically relevant symptoms and obtain baseline laboratory markers. Obtain full blood count, CRP, and ESR before or immediately after starting treatment; treatment should not be delayed if clinical suspicion is high.
- Documentation at GCA treatment initiation: document symptoms/signs and obtain baseline CBC, CRP, and ESR before or immediately after starting glucocorticoids.
- Do not delay first dose of glucocorticoid if GCA is strongly suspected.
Oncology — Hodgkin lymphoma and Castleman disease documentation
Follow oncology guideline–driven documentation when ordering ESR or CRP. For Hodgkin lymphoma, document ESR use per NCCN staging/workup and follow-up schedules; for Castleman disease document CRP and/or ESR as part of workup and note that elevated CRP (>10 mg/L) is a minor diagnostic criterion for idiopathic multicentric Castleman disease.
- Oncology-related documentation: Hodgkin lymphoma — ESR is listed as 'essential' within 6 months of diagnosis and during follow-up (every 3–6 months for 1–2 years, then every 6–12 months for 3 years, then annually).
- Castleman disease — NCCN lists LDH, CRP, and ESR as essential; elevation of CRP (>10 mg/L) is a minor diagnostic criterion and tracking CRP is recommended (ESR acceptable if CRP unavailable).
ESR versus CRP ordering guidance
Prefer CRP over ESR to detect acute phase inflammation when appropriate. CRP rises earlier (within 24 hours) and returns to normal faster after resolution of inflammation or removal of the inciting cause; ESR can remain elevated for days due to fibrinogen. Professional guidance discourages ordering ESR alone to look for acute inflammation in undifferentiated conditions.
- ESR vs CRP ordering guidance: order CRP to detect acute phase inflammation; ESR may be less sensitive in the first 24 hours and lags in normalization.
Hodgkin lymphoma — limited utility of routine ESR
Routine blood tests including ESR have limited utility for detecting Hodgkin lymphoma relapse; most recurrences are detected by history and physical exam rather than routine labs. Use ESR in Hodgkin lymphoma per guideline-specified schedules rather than routine, low‑yield testing.
- Low-yield routine ESR in Hodgkin lymphoma: acknowledge ACR guidance that routine blood work has limited role in relapse detection; follow NCCN-specified schedules when indicated.
Procedure codes and prior authorization note
Applicable CPT/HCPCS procedure codes for ordering and billing: 85651 (ESR, non-automated), 85652 (ESR, automated), and 86140 (C-reactive protein). Verify any prior authorization requirements in the payer system; this policy does not specify additional prior authorization triggers.
Step therapy
Step therapy: None specified for ESR or CRP in this policy. There are no step‑therapy requirements described for ordering these tests.
- No step therapy requirements described for ESR/CRP testing.
Literature and guideline support
This section provides literature and guideline citations supporting clinical use of CRP and ESR (eg, BSR/BHPR, EULAR, ACR, NCCN, ASCP, FDA guidance, Pediatric ID/IDSA) which inform appropriate ordering, monitoring intervals, and interpretation across conditions.
- Literature and guideline sources: BSR/BHPR for GCA and PMR; NCCN for lymphomas and Castleman disease; ASCP Choosing Wisely; ACR guidance; Pediatric Infectious Diseases Society/IDSA for AHO; FDA device and CRP assessment guidance.
Ordering Requirements
Order tests only with documented inflammatory diagnosis/suspicion
Orders for ESR or CRP should be tied to a diagnosed or suspected inflammatory condition and documented in the medical record to support medical necessity.
- Policy: Measurement of ESR and/or CRP meets coverage criteria for inflammatory conditions as specified in Note 1.
- Ordering should be tied to the diagnosed or suspected condition and documented accordingly.
Align orders with specialty guideline recommendations
When guideline‑directed, testing is typically ordered by the treating specialist (e.g., oncology for Hodgkin lymphoma, rheumatology for PMR/RA); orders should align with specialty guidance where applicable.
- EULAR/ACR and specialty guidance referenced for condition‑specific monitoring.
Order CRP/ESR with documented clinical assessment (eg, before GCA steroids)
Testing should be ordered in the context of a documented clinical assessment—for example, obtain CRP/ESR prior to or immediately after initiating high‑dose glucocorticoids for suspected GCA.
- BSR: obtain full blood count and CRP/ESR before or immediately after commencing high‑dose glucocorticoids for suspected GCA.
Comply with government policies and use CLIA‑certified labs
Orders must comply with applicable government policies and testing should be performed in CLIA‑certified laboratories; laboratory‑developed tests require in‑house validation per CMS/CLIA rules.
- Policy disclaimer: government policies (LCD/NCD/state Medicaid) take precedence.
- Testing performed in CLIA‑certified labs; LDTs are regulated by CMS and must be validated.
No ordering‑provider restrictions stated
The policy text does not impose specific restrictions on which provider types may order ESR or CRP; no specialist‑only ordering requirement is specified.
Not Covered / Low-Value Uses
Measurement of CRP and/or ESR during a routine general examination without abnormal findings is explicitly listed as not covered and may be denied. Orders must be supported by documentation of a diagnosed or suspected inflammatory condition to meet coverage criteria.
Evidence and reviews indicate that using ESR alone as a screening predictor for rheumatoid arthritis or systemic lupus erythematosus has limited predictive value and low positive predictive value in primary care populations. CRP may offer superior performance for acute-phase detection, and routine ESR-only screening is therefore of limited utility.
Routine use of ESR as a standalone surveillance test for Hodgkin lymphoma relapse has limited supporting evidence and low utility; many recurrences are detected by history and physical examination rather than routine blood testing, so standalone ESR surveillance without clinical indication is not favored.
Professional guidance from the ASCP Choosing Wisely campaign specifically recommends against ordering an ESR to look for inflammation in patients with undiagnosed conditions and instead recommends ordering CRP to detect acute-phase inflammation. This reflects ESR’s lower sensitivity early in disease and its slower return to baseline compared with CRP.
The referenced sections cited here (bibliography and related materials) do not list additional explicit tests or indications as not covered beyond those already stated in the policy excerpts.
Background and Rationale
CRP and ESR are non-specific acute-phase reactants used to detect and monitor inflammation from diverse causes. The policy specifies that measurement meets coverage criteria when ordered for identified inflammatory conditions, and conversely that testing during an otherwise normal general exam does not meet coverage criteria.
Definitions
References and Guideline Citations
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.